Keyword Analysis & Research: neurona therapeutics

Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
neurona therapeutics0.770.42481720
neurona0.5814612947
therapeutics1.820.919491512

Keyword Research: People who searched neurona therapeutics also searched

Keyword CPC PCC Volume Score
neurona therapeutics1.970.6292100
neurona therapeutics stock1.440.5545294
neurona therapeutics logo0.150.3289683
neurona therapeutics controller1.440.7318460
neurona therapeutics linkedin1.620.1424817
neurona therapeutics nrtx-10011.150.2304788
neurona therapeutics & presentation0.730.1619792
neurona therapeutics inc0.450.926999

Search Results related to neurona therapeutics on Search Engine

  • Neurona Therapeutics | NRTX-1001 Inhibitory Neuron Cell Therapy

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/

    WEBA wholly-owned pipeline of novel cell therapy products. Neurona is developing allogeneic, off-the-shelf neural cell therapies for multiple chronic neurological disorders. The pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, a first-in-class inhibitory neuron therapy for epilepsy.

    DA: 90 PA: 25 MOZ Rank: 43

  • Mission | Leadership | Investors | Neurona Therapeutics

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/about/

    WEBNeurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and developing allogeneic neural cell therapies to treat chronic diseases of the nervous system. Neurona was founded by leading-edge neuroscientists and stem cell pioneers at the University of California, San Francisco.

    DA: 53 PA: 97 MOZ Rank: 2

  • NRTX-1001 | Focal Epilepsies | Alzheimer’s | Neurona Therapeutics

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/pipeline/

    WEBThe NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression.

    DA: 92 PA: 16 MOZ Rank: 92

  • Regenerative Pluripotent Stem Cell Technology | Neurona Therapeutics

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/technology/

    WEBNeurona is developing off-the-shelf, allogeneic neuronal, glial, and gene-edited neural cell therapies for single-dose targeted repair of the nervous system. Neurona’s discovery platform is powered by regenerative pluripotent stem cell technology and used to develop proprietary manufacturing processes that produce authentic neural cell ...

    DA: 97 PA: 41 MOZ Rank: 48

  • Neurona Therapeutics Raises $120M to Advance …

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/news/press-releases/020824/

    WEBSan Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with ...

    DA: 16 PA: 54 MOZ Rank: 36

  • Neurona Therapeutics Raises $120M to Advance …

    yahoo.com

    https://finance.yahoo.com/news/neurona-therapeutics-raises-120m-advance-130000173.html

    WEBSAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...

    DA: 82 PA: 100 MOZ Rank: 71

  • Neurona Therapeutics Presents Positive Clinical Update from …

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/news/press-releases/041524/

    WEBApr 15, 2024 · Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting. – NRTX-1001 administration has been well-tolerated in all individuals treated to date. – 4 of 5 subjects treated with the lower dose of …

    DA: 42 PA: 25 MOZ Rank: 1

  • Neurona Therapeutics Raises $41.5M to Advance Neural Network

    yahoo.com

    https://finance.yahoo.com/news/neurona-therapeutics-raises-41-5m-123000966.html

    WEBSAN FRANCISCO, June 22, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics Inc., a biotherapeutics company developing neural cell therapies for the treatment of chronic neurological disorders, today...

    DA: 17 PA: 2 MOZ Rank: 69

  • Neurona Therapeutics Announces Initial Subject Dosed in First …

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/news/press-releases/062922/

    WEBSan Francisco, CA, June 29, 2022 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study.

    DA: 45 PA: 8 MOZ Rank: 24

  • Press Releases | Neurona Therapeutics

    neuronatherapeutics.com

    https://www.neuronatherapeutics.com/news/press-releases/

    WEBDec 1, 2023 · Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001. February 8, 2024 Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for …

    DA: 46 PA: 2 MOZ Rank: 84